Literature DB >> 19770470

Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.

S Llufriu1, J Castillo, Y Blanco, L Ramió-Torrentà, J Río, M Vallès, M Lozano, M D Castellà, J Calabia, A Horga, F Graus, X Montalban, Albert Saiz.   

Abstract

BACKGROUND: Plasma exchange (PE) is used to treat severe episodes of CNS demyelination unresponsive to corticosteroids. Predictors of long-term response are not well known.
METHODS: We retrospectively reviewed the medical records of 41 patients consecutively treated by PE between January 1995 and July 2007. The primary outcome was improvement at 6 months after PE defined as decrease of >or=1 point in the Expanded Disability Status Scale (EDSS) score for patients with EDSS <or=7.5 or 1.5 points with EDSS >or=8.0 or improvement of more than 2 lines in the visual acuity chart for patients with optic neuritis (ON).
RESULTS: Twenty-five patients (61%) were women, and the median age was 33 years (range 14-57 years). Twenty-three (56%) had multiple sclerosis, 2 (5%) had clinically isolated syndrome, 2 (5%) had Marburg disease, 7 (17%) had acute disseminated encephalomyelitis, 4 (10%) had neuromyelitis optica, 2 (5%) had idiopathic ON, and 1 (2%) had idiopathic transverse myelitis. The median EDSS score before the attack was 1.0 (range 0-6.5). At PE onset, the median EDSS score was 7.0 (range 3.0-9.5). Sixteen patients (39%) improved at discharge, and 26 (63%) improved at 6 months. In the multivariate analysis, early initiation of PE (odds ratio [OR] 6.29, 95% confidence interval [CI] 1.18-52.96) and improvement at discharge (OR 7.32, 95% CI 1.21-44.38) were significantly associated with response at 6 months.
CONCLUSIONS: Plasma exchange (PE) was associated with clinical improvement in 63% of patients at 6 months. Early initiation of PE and improvement at discharge were predictors of this response. Twelve patients (48%) who did not improve early did so during follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19770470     DOI: 10.1212/WNL.0b013e3181b879be

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

1.  Plasmapheresis: are bigger studies necessarily better?

Authors:  Brian Weinshenker
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

2.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

3.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

4.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

5.  Plasma exchange in acute attacks of demyelinating diseases of the central nervous system: clinical outcomes and predictors of response.

Authors:  Michael A Palacios-Mendoza; María L Martínez Ginés; Pedro J Melgarejo Otálora; Juan P Cuello; Antonio Sánchez-Soblechero; Alberto Lozano Ros; José A Aparcero-Suero; Sergio López Anguita; Fernando Anaya; José M García Domínguez
Journal:  Neurol Sci       Date:  2020-04-04       Impact factor: 3.307

6.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

7.  Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.

Authors:  Sotaro Mori; Takuji Kurimoto; Kaori Ueda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2018-05-25       Impact factor: 2.447

8.  Neuromyelitis optica.

Authors:  William M Carroll; Kazuo Fujihara
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

9.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 10.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.